Table 2.

BAL cell types by H&E staining and by flow cytometry at days 2 and 4 after infection with B1 or CP52 and treatment with nIg F(ab)2 or anti-SP F(ab)2 Ab

Type of analysisChallenge + treatmentCell typebDay 2 p.i.Day 4 p.i.
Range, % positiveMedian % (P value)aRange, % positiveMedian % (P value)a
H&E stainingB1 + nIgMacrophage85–9589 (>0.10)80–9385 (>0.10)
PMN0–42 (>0.10)0–43 (>0.10)
Eosinophil1–54 (>0.10)0–22 (>0.10)
Lymphocyte4–85 (>0.10)2–1210 (>0.10)
B1 + anti-SPMacrophage88–9894 78–9485 
PMN00 1–52 
Eosinophil00 0–62 
Lymphocyte5–146 8–1511 
CP52 + nIgMacrophage80–9588 (>0.10)88–9690 (>0.10)
PMN0–43 (>0.10)0–62 (>0.10)
Eosinophil00 (>0.10)1–52 (>0.10)
Lymphocyte6–129 (>0.10)4–106 (>0.10)
CP52 + anti-SPMacrophage90–9894 80–9488 
PMN00 1–62 
Eosinophil00 0–62 
Lymphocyte4–156 5–128 
Flow cytometryB1 + nIgCD418–2520 (>0.10)19–2522 (>0.10)
CD86–128 (>0.10)8–1512 (>0.10)
B2206–107 (>0.10)4–65 (>0.10)
DX54–96 (<0.01)4–86 (<0.01)
RB6-8C54–64 (>0.10)9–1412 (>0.10)
B1 + anti-SPCD415–2016 21–2825 
CD86–86 6–128 
B2202–65 4–76 
DX510–1712 15–2419 
RB6-8C54–65 6–128 
CP52 + nIgCD419–2524 (>0.10)25–3028 (>0.10)
CD89–1510 (>0.10)10–1512 (>0.10)
B2204–64 (>0.10)3–64 (>0.10)
DX514–1815 (>0.01)18–2420 (>0.10)
RB6-8C58–1410 (<0.01)15–2018 (<0.01)
CP52 + anti-SPCD416–2120 20–3026 
CD85–128 5–1410 
B2202–64 2–85 
DX58–1410 15–2018 
RB6-8C54–105 6–1210 
  • a For comparison between nIg and anti-SP-treated mice given the same challenge virus.

  • b A lymphocyte gate was used to select 10,000 events for CD3+ and B220+ lymphocytes; 10,000 ungated events were used for analysis of DX5+, RB6-8C5+, and CD11b+ cells.